FOR RESEARCH PURPOSES ONLY, NOT INTENTED FOR HUMAN CONSUMPTION Retatrutide is a synthetic peptide-based triple receptor agonist that simultaneously targets the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This balanced multi-agonism is designed to enhance glycemic control, reduce body weight, and improve metabolic efficiency through synergistic modulation of energy intake and expenditure.

Mechanistically, Retatrutide promotes glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and enhances satiety signaling within the central nervous system. Activation of the glucagon receptor component contributes to increased lipid oxidation and energy expenditure, complementing its anorectic effects.

In clinical studies, Retatrutide has demonstrated substantial reductions in body weight and improvements in metabolic parameters, suggesting its potential as a next-generation therapeutic for obesity, type 2 diabetes, and related metabolic disorders.